The Russian Direct Investment Fund (RDIF) and the HimRar company will supply the coronavirus drug Avifavir to 17 countries, including Turkmenistan, reports mass media.
The drug is going to be delivered to Argentina, Bulgaria, Chile, Colombia, Honduras, Brazil, Panama, Uruguay, Ecuador, Kuwait, El Salvador, Paraguay, Serbia, Slovakia, Saudi Arabia, South Africa, and the United Arab Emirates. It is noted that the drug has already been delivered to Belarus, Kazakhstan, Bolivia, Kyrgyzstan, Uzbekistan, and Turkmenistan.
Looking back, that Avifavir was registered by the Ministry of Health of the Russian Federation in May and became the world’s first drug based on favipiravir, which is approved for the treatment of coronavirus. Since June, the drug has been delivered to clinics in 74 regions of the Russian Federation.
Avifavir, which was developed by the Russian Direct Investment Fund, received a registration certificate from the Ministry of Health at the end of May and became the world’s first anti-coronavirus drug containing the active ingredient favipiravir. In July, it was included in the list of guideline for the prevention, diagnosis and treatment of COVID-19.
Recently, the Ministry of Health of the Russian Federation has also allowed out-patient use of two local products from the coronavirus with the international non-proprietary name Favipiravir – Coronavir of R-Pharm company and Areplivir of Promomed company, which heretofore were used for the treatment of patients at in-patient clinics.